Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E M Jaffee

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Cancer Research|July 26, 2000
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceR T Reilly, M B Gottlieb, A M Ercolini, et al.
The Cancer Journal From Scientific American|June 5, 1998
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trialsE M Jaffee, M Schutte, J Gossett, et al.
Human Gene Therapy|March 1, 1995
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinomaA J Berns, S Clift, L K Cohen, et al.
The Journal of Urology|March 1, 1994
Demonstration of a rational strategy for human prostate cancer gene therapyM G Sanda, S R Ayyagari, E M Jaffee, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 5, 2000
Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous systemM G Ewend, R C Thompson, R Anderson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 3, 1996
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene productA Y Huang, P H Gulden, A S Woods, et al.
Gene Therapy|July 5, 2001
Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectorsJ G Wesseling, P J Bosma, V Krasnykh, et al.
International Journal of Radiation Oncology, Biology, Physics|November 10, 2000
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survivalA Chakravarthy, R A Abrams, C J Yeo, et al.
Cancer Research|June 5, 2001
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinomaP Argani, C Rosty, R E Reiter, et al.
Human Gene Therapy|September 19, 1998
A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinomaE M Jaffee, R Abrams, J Cameron, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Cancer Research|July 26, 2000
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceR T Reilly, M B Gottlieb, A M Ercolini, et al.
The Cancer Journal From Scientific American|June 5, 1998
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trialsE M Jaffee, M Schutte, J Gossett, et al.
Human Gene Therapy|March 1, 1995
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinomaA J Berns, S Clift, L K Cohen, et al.
The Journal of Urology|March 1, 1994
Demonstration of a rational strategy for human prostate cancer gene therapyM G Sanda, S R Ayyagari, E M Jaffee, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 5, 2000
Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous systemM G Ewend, R C Thompson, R Anderson, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 3, 1996
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene productA Y Huang, P H Gulden, A S Woods, et al.
Gene Therapy|July 5, 2001
Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectorsJ G Wesseling, P J Bosma, V Krasnykh, et al.
International Journal of Radiation Oncology, Biology, Physics|November 10, 2000
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survivalA Chakravarthy, R A Abrams, C J Yeo, et al.
Cancer Research|June 5, 2001
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinomaP Argani, C Rosty, R E Reiter, et al.
Human Gene Therapy|September 19, 1998
A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinomaE M Jaffee, R Abrams, J Cameron, et al.
Pageof 5